Stroke: 纤维蛋白凝块特性改变可以预测使用利伐沙班的房颤患者的卒中和出血情况

2019-01-13 MedSci MedSci原创

利伐沙班(rivaroxaban)可以用于治疗房颤疾病,但是血凝块渗透性的改变是否可以预测房颤患者的出血或卒中发生率目前还没有文献进行研究。因此,本项研究旨在探究这方面的问题。

背景和目的
利伐沙班(rivaroxaban)可以用于治疗房颤疾病,但是血凝块渗透性的改变是否可以预测房颤患者的出血或卒中发生率目前还没有文献进行研究。因此,本项研究旨在探究这方面的问题。

方法
在本项队列研究中,研究人员在使用利伐沙班20 mg / d(76.3%)或15 mg / d(23.7%)至少3个月的患者中挑选了 232例房颤患者。血浆凝块渗透性(K s)是纤维蛋白网络密度的量度,自利伐沙班以摄入后24至30小时测定此纤维蛋白凝块的特征,并同时记录缺血性脑血管事件和出血情况。

结果
本项研究的中位随访期间是48个月,K s水平低于中位数(6.8 cm 2 ·10 -9)的患者卒中患病率较高(5.84VS0.88%; P <0.0001),出血的水平风险也较高(7.06VS0.88%; P <0.0001)。死亡率与K s水平无关。较低的 Ks预测脑血管缺血事件(HR:6.64; 95%CI,2.2-20.1)和相关的出血(HR:7.38; 95%CI,2.58-21.10)。在K s高于中位数的患者中观察到轻微出血(50.9%VS14.7%; P<0.0001)。多变量Cox回归分析显示,较低的K s会增加卒中风险(HR,6.51; 95%CI,2.14-19.75)和出血风险(HR,9.68; 95%CI,3.21-29.18) 。

结论
房颤患者的凝块渗透性降低可以预测利伐沙班治疗期间血栓栓塞和临床相关的出血事件,而较松散的凝块网络易患轻微出血。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1997267, encodeId=ede3199e267a9, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Sun Oct 13 00:51:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614494, encodeId=9aaa16144942b, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Tue Jan 15 04:51:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026265, encodeId=155c1026265d6, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sun Jan 13 16:51:00 CST 2019, time=2019-01-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1997267, encodeId=ede3199e267a9, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Sun Oct 13 00:51:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614494, encodeId=9aaa16144942b, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Tue Jan 15 04:51:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026265, encodeId=155c1026265d6, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sun Jan 13 16:51:00 CST 2019, time=2019-01-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1997267, encodeId=ede3199e267a9, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Sun Oct 13 00:51:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614494, encodeId=9aaa16144942b, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Tue Jan 15 04:51:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026265, encodeId=155c1026265d6, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sun Jan 13 16:51:00 CST 2019, time=2019-01-13, status=1, ipAttribution=)]
    2019-01-13 健健

    卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!

    0